---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-004982"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2026-07-29T12:15:16+00:00"
generated_at: "2026-07-29T12:23:32.792190+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Filana Therapeutics Q2 2026 net loss $8.6M; cash $82.7M; clinical hold on TSC trial continues

## Summary
- Net loss of $8.6M ($0.18 per share) vs $44.2M ($0.92) in Q2 2025; improvement due to no repeat of $31.25M litigation loss.
- Cash and equivalents $82.7M at June 30, 2026, down from $95.5M at Dec 31, 2025; no debt.
- R&D expenses $3.3M (down 35% YoY) as Alzheimer's program phased out; G&A $6.1M (down 85% YoY).
- Paid $31.25M into escrow on July 23, 2026 for securities litigation settlement; cash restricted pending court approval.
- Unrestricted cash at year-end 2026 expected $36-40M; second-half 2026 operating cash use $11-15M plus litigation funding.

## SEC filing metadata
- accession: 0001171843-26-004982
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2026-07-29T12:15:16+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000117184326004982/0001171843-26-004982-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000117184326004982/f8k_072826.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-004982
- JSON: https://secwatch.observer/filing/0001171843-26-004982.json
- Plain text: https://secwatch.observer/filing/0001171843-26-004982.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.